Клиническая и социально-экономическая эффективность пролонгированной формы рисперидона (Рисполепт Конста) при шизофрении

Background. The use of modern long-lasting forms of antipsychotics is one of the rational approaches to improvement of compliance of patients with schizophrenia and efficacy of treatment.The aim of the study: was to evaluate clinical and economic efficacy of Rispolept Consta in treatment of schizophrenia patients under conditions of routine out-patient clinical practice.Material and Methods. The efficacy of Rispolept Consta prescription to patients with schizophrenia in the practice of work of psychoneurological dispensary (PND) was investigated in observational study. 29 patients with schizophrenia received Rispolept Consta during a year. Economic efficacy was estimated by comparing the frequency and duration of institutionalizations in mental hospital, out-patient treatment, out-patient cessation of exacerbations, and emergency calls during the year of treatment with Rispolept Consta with preceding period of therapy of the same duration.Results. Significant reduction of frequency and duration of hospitalizations, relapses, suicides, episodes of aggression, reduction in expenditures for treatment was shown. Improvement in compliance of patients was noticed, as well as achievement of regular PND attendance, improvement of labor activity of patients, change in the structure of concomitant therapy towards reduction in the number of drugs from other groups.Conclusion. Long-term treatment with Rispolept Consta in everyday practice contributes to clinical improvement of mental status of schizophrenia patients, their functional rehabilitation and resource saving in the system of mental health services.

шизофрения, лечение, Рисполепт Конста, эффективность, комплаентность, экономический эффект, schizophrenia, treatment, Rispolept Consta, efficacy, compliance, economic effect

1. Seltzer A., Hoffman B.F. Drug compliance of the psychiatric patient. Can. Fam. Physician. 1980;26:725-727

2. Любов Е.Б. Стоимостный анализ шизофрении в России. Психиатрия и психофармакотерапия. 2013;15(1):8-20

3. Оленева Е.В., Капилетти С.Г., Рывкин П.В., Ладыженский М.Я. Рисполепт Конста - 10 лет применения в России: некоторые итоги. Современная терапия психических расстройств. 2015;1:10-24

4. International Observational Registry on Schizophrenia (InORS) Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study Presented at the 2013 European Congress of Psychiatry (EPA). 6-9 April 2013. Nice, France

5. Любов Е.Б. Многосторонний анализ эффективности длительного лечения шизофрении рисполептом конста в повседневной психиатрической практике (данные 12 месяцев лечения пациентов российской когорты между- народного исследования e-star). Социальная и клиническая психиатрия. 2011;21(3):66-73